Cargando…

Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma

Currently, metastatic pancreatic cancer is associated with disappointing survival outcomes. This is largely due to a rapid progression of the disease and a precipitous deterioration in the health of affected individuals, especially elderly patients who are often unable to tolerate chemotherapy. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Wang, Yaomei, Kellner, Daniel B., Xu, Linping, Mai, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Society of Experimental and Clinical Immunology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637394/
https://www.ncbi.nlm.nih.gov/pubmed/26557033
http://dx.doi.org/10.5114/ceji.2015.52833
_version_ 1782399804347777024
author Li, Wei
Wang, Yaomei
Kellner, Daniel B.
Xu, Linping
Mai, Ling
author_facet Li, Wei
Wang, Yaomei
Kellner, Daniel B.
Xu, Linping
Mai, Ling
author_sort Li, Wei
collection PubMed
description Currently, metastatic pancreatic cancer is associated with disappointing survival outcomes. This is largely due to a rapid progression of the disease and a precipitous deterioration in the health of affected individuals, especially elderly patients who are often unable to tolerate chemotherapy. The aim of this study was to evaluate the efficacy and safety of adoptive immunotherapy using cytokine-induced killer cells (CIK) as a first-line treatment for metastatic pancreatic cancer. Between December 2010 and June 2012 eight patients were enrolled in this study. All participants were elderly, suffering from metastatic pancreatic cancer, and unable to tolerate chemotherapy. All patients in this study received R-CIK therapy only as a first-line treatment. In the eight patients, 1 had complete response (CR), 5 had stable disease (SD) and 2 had progression disease (PD). Therefore, the overall response rate (ORR) was 12.5% (1/8) and the disease control rate (DCR) was 75.0% (6/8 patients). The 1-year survival rate was 37.5%, and the median overall survival time (mOS) was 13.04 months (95% CI: 5.9-20.2). The results indicated that no significant positive or negative predictive factors were identified by univariate analysis. The main adverse effect of R-CIK was fever and the side effect rate was 25.0% (2/8). Adoptive immunotherapy using R-CIK cells showed comparable OS to survival data seen in previous trials assessing conventional chemotherapies in elderly patients and the adverse effect is less pronounced.
format Online
Article
Text
id pubmed-4637394
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Polish Society of Experimental and Clinical Immunology
record_format MEDLINE/PubMed
spelling pubmed-46373942015-11-09 Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma Li, Wei Wang, Yaomei Kellner, Daniel B. Xu, Linping Mai, Ling Cent Eur J Immunol Original Article Currently, metastatic pancreatic cancer is associated with disappointing survival outcomes. This is largely due to a rapid progression of the disease and a precipitous deterioration in the health of affected individuals, especially elderly patients who are often unable to tolerate chemotherapy. The aim of this study was to evaluate the efficacy and safety of adoptive immunotherapy using cytokine-induced killer cells (CIK) as a first-line treatment for metastatic pancreatic cancer. Between December 2010 and June 2012 eight patients were enrolled in this study. All participants were elderly, suffering from metastatic pancreatic cancer, and unable to tolerate chemotherapy. All patients in this study received R-CIK therapy only as a first-line treatment. In the eight patients, 1 had complete response (CR), 5 had stable disease (SD) and 2 had progression disease (PD). Therefore, the overall response rate (ORR) was 12.5% (1/8) and the disease control rate (DCR) was 75.0% (6/8 patients). The 1-year survival rate was 37.5%, and the median overall survival time (mOS) was 13.04 months (95% CI: 5.9-20.2). The results indicated that no significant positive or negative predictive factors were identified by univariate analysis. The main adverse effect of R-CIK was fever and the side effect rate was 25.0% (2/8). Adoptive immunotherapy using R-CIK cells showed comparable OS to survival data seen in previous trials assessing conventional chemotherapies in elderly patients and the adverse effect is less pronounced. Polish Society of Experimental and Clinical Immunology 2015-08-03 2015 /pmc/articles/PMC4637394/ /pubmed/26557033 http://dx.doi.org/10.5114/ceji.2015.52833 Text en Copyright © Central European Journal of Immunology 2015 http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Li, Wei
Wang, Yaomei
Kellner, Daniel B.
Xu, Linping
Mai, Ling
Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
title Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
title_full Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
title_fullStr Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
title_full_unstemmed Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
title_short Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
title_sort efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637394/
https://www.ncbi.nlm.nih.gov/pubmed/26557033
http://dx.doi.org/10.5114/ceji.2015.52833
work_keys_str_mv AT liwei efficacyofcytokineinducedkillercellsinthetreatmentofelderlypatientswithmetastaticpancreaticadenocarcinoma
AT wangyaomei efficacyofcytokineinducedkillercellsinthetreatmentofelderlypatientswithmetastaticpancreaticadenocarcinoma
AT kellnerdanielb efficacyofcytokineinducedkillercellsinthetreatmentofelderlypatientswithmetastaticpancreaticadenocarcinoma
AT xulinping efficacyofcytokineinducedkillercellsinthetreatmentofelderlypatientswithmetastaticpancreaticadenocarcinoma
AT mailing efficacyofcytokineinducedkillercellsinthetreatmentofelderlypatientswithmetastaticpancreaticadenocarcinoma